Using engineered antibodies to target tau proteins in Alzheimer's disease
Vectorized scFv antibodies to treat tau pathology in Alzheimer's disease: enhancing epitope targeting and delivery strategies
This study is testing a new treatment for Alzheimer's disease that uses specially designed tiny antibodies to help clear harmful tau proteins from the brain, aiming to improve the health and well-being of people living with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Feinstein Institute for Medical Research NIH-funded |
| Lab location | 1 site (Manhasset, United States) |
| Project ID | NIH-10866347 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for Alzheimer's disease by using engineered antibodies that specifically target tau proteins, which are implicated in the disease's progression. The approach involves using smaller antibody fragments called scFv, which can penetrate the blood-brain barrier more effectively and are less likely to cause inflammation. By delivering these fragments through viral vectors, the research aims to improve the clearance of tau pathology in the brain, potentially leading to better outcomes for patients with Alzheimer's. The study builds on previous findings in animal models, seeking to enhance the effectiveness and safety of tau-targeted therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's disease.
Not a fit: Patients with other forms of dementia or those who are not diagnosed with Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for Alzheimer's disease, potentially slowing its progression and improving quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting tau pathology in animal models, indicating that this approach may be effective, although it is still being explored in human applications.
Where this research is happening
Manhasset, United States
- Feinstein Institute for Medical Research — Manhasset, United States (Active)
Researchers
- Principal investigator: D'abramo, Cristina — Feinstein Institute for Medical Research
- Study coordinator: D'abramo, Cristina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.